Geron Corp Files 8-K on Financials

Ticker: GERN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 886744

Geron Corp 8-K Filing Summary
FieldDetail
CompanyGeron Corp (GERN)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $45 million, $46 m, $250 million, $260 m
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, sec-filing

TL;DR

Geron Corp dropped an 8-K on Jan 13th detailing financials and operations.

AI Summary

Geron Corporation filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Foster City, California.

Why It Matters

This filing provides investors with crucial updates on Geron Corporation's financial health and operational performance, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Numbers

  • 000-20859 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 75-2287752 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • GERON CORP (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • Foster City, CA (location) — Principal executive offices
  • January 13, 2025 (date) — Date of earliest event reported

FAQ

What specific financial information is being reported in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details would be within the attached documents.

What is the significance of the 'Regulation FD Disclosure' item?

This indicates that the company is making disclosures that could be considered material non-public information, ensuring fair and simultaneous dissemination to all investors.

When was Geron Corporation incorporated?

The filing states the company is incorporated in Delaware.

What is the primary business of Geron Corp based on its SIC code?

Geron Corp's Standard Industrial Classification (SIC) code is 2834, which corresponds to 'Pharmaceutical Preparations'.

Where are Geron Corporation's principal executive offices located?

The principal executive offices are located at 919 E. Hillsdale Blvd., Suite 250, Foster City, CA 94404.

Filing Stats: 822 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-01-13 08:05:16

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value GERN The Nasdaq Stock Mar
  • $45 million — , 2024 are expected to be approximately $45 million to $46 million, (ii) operating expenses
  • $46 m — cted to be approximately $45 million to $46 million, (ii) operating expenses for the
  • $250 million — , 2024 are expected to be approximately $250 million to $260 million, and (iii) cash, cash e
  • $260 m — ted to be approximately $250 million to $260 million, and (iii) cash, cash equivalents
  • $500 million — , 2024 are expected to be approximately $500 million. The aforementioned financial informati

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. Geron Corporation (the "Company" or "Geron") will participate in various meetings with securities analysts and investors during the 43 rd Annual J.P. Morgan Healthcare Conference the week of January 13, 2025, and will utilize a presentation handout during those meetings. Such presentation handout discloses that Geron expects to report that (i) net revenue from U.S. sales of RYTELO during the fourth quarter ended December 31, 2024 are expected to be approximately $45 million to $46 million, (ii) operating expenses for the year ended December 31, 2024 are expected to be approximately $250 million to $260 million, and (iii) cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024 are expected to be approximately $500 million. The aforementioned financial information is included on slide #17 of the presentation handout, as furnished in Exhibit 99.1 to this Current Report, and is incorporated herein by reference. The Company has not yet completed its financial close process for the quarter and year ended December 31, 2024. These estimates of the Company's net revenue, operating expenses and cash, cash equivalents, restricted cash and marketable securities for the applicable 2024 periods presented are preliminary, unaudited and are subject to change upon completion of the Company's financial statement closing procedures and the audit of the Company's consolidated financial statements.

01

Item 7.01 Regulation FD Disclosure. Geron will participate in various meetings with securities analysts and investors during the 43 rd Annual J.P. Morgan Healthcare Conference the week of January 13, 2025, and will utilize a presentation handout during those meetings. The presentation handout, together with a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation handout, is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The presentation handout will also be made available in the Investors section of Geron's website, located at www.geron.com . The information contained in Items 2.02 and 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act, and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 January 2025 Corporate Presentation 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GERON CORPORATION Date: January 13, 2025 By: /s/ Scott A. Samuels Name: Scott A. Samuels Title: Executive Vice President, Chief Legal Officer and Corporate Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.